Anhedonia in bipolar depression treated with ketamine
Anhedonia in bipolar depression treated with ketamine
StatusVoR
Alternative title
Authors
Arciszewska-Leszczuk, Aleksandra
Wilkowska, Alina
Wiglusz, Mariusz S.
Gałuszko-Węgielnik, Maria
Cubała, Wiesław J.
Monograph
Monograph (alternative title)
Date
2024-02-04
Publisher
Journal title
Bipolar Disorders
Issue
4
Volume
26
Pages
Pages
356-363
ISSN
ISSN of series
Access date
2024-02-04
Abstract PL
Abstract EN
Background: Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently, there is no approved treatment specifically targeting anhedonia. Emerging evidence suggests that ketamine possesses anti-anhedonic properties in individuals with depression.
Objectives: The aim of this naturalistic open-label study was to investigate the effect of add-on ketamine treatment on anhedonia in treatment resistant bipolar depression.
Methods: Our main interest was the change in patient-reported (Snaith-Hamilton Pleasure Scale) and rater-based anhedonia measure (Montgomery–Åsberg Depression Rating Scale-anhedonia subscale). The secondary aim was to analyze the score change in three Inventory of Depressive Symptomatology-Self Report (IDS-SR) domains: mood/cognition, anxiety/somatic, and sleep. Patients underwent assessments at several time points, including baseline, after the third, fifth, and seventh ketamine infusions. Additionally, a follow-up assessment was conducted 1 week following the final ketamine administration.
Results: We found improvement in anhedonia symptoms according to both patient-reported and rater-based measures. The improvement in IDS-SR domains was most prominent in anxiety/somatic factor and mood/cognition factor, improvement in sleep factor was not observed. No serious adverse events occurred.
Conclusion: Add-on ketamine seems to be a good choice for the treatment of anhedonia in treatment resistant bipolar depression. It also showed a good effect in reducing symptoms of anxiety in this group of patients. Considering unmet needs and the detrimental effect of anhedonia and anxiety, more studies are needed on ketamine treatment in resistant bipolar depression.
Abstract other
Keywords PL
Keywords EN
anhedonia
anxiety
ketamine IDS- SR domains
sleep
treatment resistant bipolar depression
anxiety
ketamine IDS- SR domains
sleep
treatment resistant bipolar depression
Keywords other
Exhibition title
Place of exhibition (institution)
Exhibition curator
Type
License type
Funder
Time range from
Time range to
Contact person name
Related publication
Related publication
Grant/project name
Collections
Views
19Acquisition Date4.04.2025
Downloads
3Acquisition Date4.04.2025
Altmetrics©
Dimensions
Google Scholar
